- P-ISSN 2233-4203
- E-ISSN 2093-8950
- Apply for Authority
- P-ISSN2233-4203
- E-ISSN2093-8950
Article Detail
Home > Article Detail
Inhibitory effect of honokiol and magnolol on cytochrome P450 enzyme activities in human liver microsomes
Mass Spectrometry Letters / Mass Spectrometry Letters, (P)2233-4203; (E)2093-8950
2013, v.4 no.2, pp.34-37
https://doi.org/10.5478/MSL.2013.4.1.34
(Kyungpook National University)
(Kyungpook National University)
(Kyungpook National University)
Joo,
J., &
Liu,
K.
(2013). Inhibitory effect of honokiol and magnolol on cytochrome P450 enzyme activities in human liver microsomes. Mass Spectrometry Letters, 4(2), 34-37, https://doi.org/10.5478/MSL.2013.4.1.34
- Downloaded
- Viewed
Abstract
Honokiol and magnolol, the major bioactive neolignans of magnolia officinalis, are the most important constituents ofthe crude drug prescriptions that are used in the therapy of neuroses and various nervous disorders. There have been limitedreports on the effects of neolignoid compounds on human cytochrome P450 activity. Therefore, the inhibitory effects of honokioland magnolol on seven human cytochrome P450 s were evaluated in human liver microsomes. Honokiol and magnololshowed the most potent inhibition of CYP1A2-mediated phenacetin O-deethylase activity (IC50 values of 3.5 and 5.4 mM,respectively) among the seven P450s tested. These in vitro data indicate that neolignan compounds can inhibit the activity ofCYP1A2 and suggest that these compounds should be examined for potential pharmacokinetic drug interactions in vivo.
- keywords
- Cytochrome P450, Drug interaction, Honokiol, Magnolol, Microsomes
Reference
1
Lee, Y. J. (2011). . Pharmacol Ther, 130, 157-.
2
Teng, C. M. (1988). . Thromb Res, 50, 757-.
3
Zhang, W. W. (2005). . World J. Gastroenterol, 11, 4414-.
4
Wang, J. P. (1995). . J. Pharm. Pharmacol, 47, 857-.
5
Kuribara, H. (1999). . Phytother Res, 13, 593-.
6
Tsai, S. K. (1996). . Planta Med, 62, 503-.
7
Kim, M. J. (2005). . Rapid Commun. Mass Spectrom, 19, 2651-.
8
Joo, J. (2013). . Biopharm. Drug Dispos, , -.
9
Foti, R. S. (2008). . Drug Metab. Dispos, 36, 523-.
10
Kumar, V. (2006). . Drug Metab. Dispos, 34, 1966-.
11
Berthou, F. (1991). . Drug Metab. Dispos, 19, 561-.
12
Sarkar, M. A. (1994). . Drug Metab. Dispos, 22, 827-.
- Submission Date
- 2013-04-09
- Revised Date
- 2013-06-27
- Accepted Date
- 2013-06-27
Other articles from this issue
- An Automated High Throughput Proteolysis and Desalting Platform for Quantitative Proteomic Analysis
- Fragmentation Behavior Studies of Chalcones Employing Direct Analysis in Real Time (DART)
- Inhibitory effect of honokiol and magnolol on cytochrome P450 enzyme activities in human liver microsomes
- Enhanced Detection of Glycans by MALDI-TOF Mass Spectrometry Using a Binary Matrix of 2,5-Dihydroxybenzoic Acid and 2,6-Dihydroxybenzoic Acid
- more
Recommanded Articles
This website recommended the use the Chrome browser for journal website.